pharmaphorum June 18, 2025
Phil Taylor

A smartphone app developed by Otsuka and digital health firm Click Therapeutics has been launched in Great Britain – its first European market – as a prescription digital therapeutic (DTx) for people living with depression.

Called Rejoyn (formerly CT-152), it is the first prescription-only app for depressive disorder episodes to be made available in GB and is currently available within select NHS trusts after being trialled last year. It is UKCA-marked as software-as-a-medical-device (SaMD) and available through the App Store and Google Play, but requires a referral from a doctor or therapist.

The DTx is designed to be used alongside the existing care plan for people with depression to manage their emotions more effectively using cognitive behavioural therapy (CBT) techniques...

Today's Sponsors

Venturous
ZeOmega

Today's Sponsor

Venturous

Continue Reading

 
Topics: Apps, Digital Health, Mental Health, Provider, Technology
Related Articles:
Two App Updates Make The Apple Watch Even Better For Fitness Tracking
The Smart Sleep Alarm Is The Holy Grail Of Health Tracking - 2
A Healthcare Tech Challenge: Cleaning Out the (App) Basement
NHS App to become national channel for the ‘shift to prevention’
Amazon Adds AI Assistant to One Medical App

Share Article